BAKU, Azerbaijan, Sept. 7
By Fakhri Vakilov – Trend:
The preliminary results of the third phase of clinical trials of the Uzbek- Chinese ZF-UZ-VAC 2001 vaccine in Uzbekistan were announced by the director of the Research Institute of Virology Erkin Musabaev, Trend reports citing Ministry of Innovative Development.
Data are presented as of July 1.
All three doses were received by 5,520 volunteers, among them 209 people over 60 years old. According to the rules of clinical trials, half of the volunteers (2,757 people, or 49.95 percent, of which 102 are over 60 years old) were vaccinated with the vaccine, the rest (2,763 people, or 50.05 percent, of which 107 are over 60 years old) received a placebo (a substance not which has no medicinal properties).
The number of cases of COVID-19 within 6 months after the introduction of all three doses: 20 people among those who received the vaccine (0.73 percent) and 73 people (2.64 percent) among those who received placebo. Among the latter, there is also 1 person over 60 years old, and among the elderly people who received the vaccine, no cases have been identified. At the same time, a moderate course was observed in 4 (0.15 percent) and 15 (0.54 percent) people, respectively, severe and extremely severe - only in 1 person with placebo (0.04 percent).
Lethal cases were not detected among those who were vaccinated with the vaccine, nor among those who received a placebo.
In the group of those who received the vaccine, “adverse events” occurred in 8 people (0.29 percent), of those who received placebo - in 5 people (0.18 percent).
“Of all the vaccines that are currently being used in Uzbekistan, it can be said that the mildest vaccine with the least side effects is the Sino-Uzbek vaccine,” added Erkin Musabayev.
Recall that at the end of August, the results of the third phase of clinical trials of the ZF-2001 coronavirus vaccine, conducted in Hunan province (China), as well as in Uzbekistan, Indonesia, Pakistan and Ecuador, were announced. The vaccine efficacy after the third dose was 81.76 percent for all strains, 92.93 percent against the "British" strain and 77.54 percent against the "delta" strain. The vaccine has also been shown to be 100 percent effective against fatal and severe cases.
---
Follow the author on Twitter:@vakilovfaxri